Effect of oxytocin receptor antagonist (GSK-221-149-A) on mandibular bone porosity in peri-menopausal rats

The period of peri-menopause (PMP) is characterized by hormonal fluctuations that impact the strength and health of bones. Oxytocin (OX), a small peptide known to be present in bone tissue, is the focus of this study. The objective of this research is to gain a better understanding of how OX precisely functions in the remodeling process of the mandibular bone. This understanding is seen as a crucial step in preventing the loss of both cortical and trabecular bone during the PMP. The current findings indicate that OX plays a role in preserving both compact and trabecular bone tissues, enhancing the mineral-to-matrix ratio, and regulating bone markers. Furthermore, it reduces porosity in both cortical and trabecular bone levels. Interestingly, these effects are reversed when an oxytocin receptor antagonist (GSK-221,149-A) is introduced, suggesting that OX’s bone-preserving action is primarily mediated through the oxytocin receptor, rather than other mechanisms.